![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
Sponsored by: |
Epimmune |
---|---|
Information provided by: | Epimmune |
ClinicalTrials.gov Identifier: | NCT00054912 |
EP2101 is a new cancer vaccine containing 10 different peptide antigens. The vaccine is designed to activate the immune system to develop a response against tumor cells in order to delay or prevent the recurrence of cancer.
This study will test the safety and measure the level of immune stimulating capability of EP2101 in patients with Colon Cancer.
Condition | Intervention | Phase |
---|---|---|
Colonic Neoplasms Colorectal Neoplasms |
Biological: EP2101 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study |
Official Title: | An Open Label, Multi-Center Safety and Tolerance Study of EP2101 Peptide Vaccine in Patients With Stage III Colon Cancer |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, California | |
University of Southern California School of Medicine | |
Los Angeles, California, United States, 90033 | |
University of California, San Diego | |
San Diego, California, United States, 92037 | |
United States, Florida | |
Cancer Centers of Florida | |
Orlando, Florida, United States, 32806 | |
United States, New York | |
New York Oncology Hematology | |
Albany, New York, United States, 12208 | |
United States, North Carolina | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Texas | |
Mary Crowley Medical Research Center | |
Dallas, Texas, United States, 75246 | |
Tyler Cancer Center | |
Tyler, Texas, United States, 75702 | |
United States, Washington | |
University of Washington | |
Seattle, Washington, United States, 91895 | |
Cancer Care Northwest | |
Spokane, Washington, United States, 99218 |
Study ID Numbers: | EP2101-102 |
Study First Received: | February 12, 2003 |
Last Updated: | April 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00054912 History of Changes |
Health Authority: | United States: Food and Drug Administration |
vaccine colon cancer colorectal |
neoplasm Colonic Cancer Colon Cancer Cancer of the Colon |
Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases Gastrointestinal Neoplasms |
Intestinal Diseases Rectal Diseases Colonic Neoplasms Intestinal Neoplasms Colorectal Neoplasms |
Neoplasms Digestive System Diseases Neoplasms by Site Digestive System Neoplasms Gastrointestinal Diseases Colonic Diseases |
Gastrointestinal Neoplasms Intestinal Diseases Rectal Diseases Colonic Neoplasms Intestinal Neoplasms Colorectal Neoplasms |